Peptide Library

Human study PLS-00141

Aberrant Expression of Thymosin Beta-4 Correlates With Advanced Disease and BRAF V600E Mutation in Thyroid Cancer.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Aberrant Expression of Thymosin Beta-4 Correlates With Advanced Disease and BRAF V600E Mutation in Thyroid Cancer.primary · The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2022-10-01 · PMID 36321670 · DOI

Design and participants

Design
Cross-sectional study
Population
Patients with benign thyroid disorders and thyroid malignancies, including a subset with differentiated thyroid cancer whose tissue was assessed for TMSB4X expression.
Conditions
Thyroid cancer, Benign thyroid disorders
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): TMSB4X expression was aberrantly increased in several thyroid cancer types and correlated with advanced disease features. The authors suggest it may be a downstream effector of the BRAF V600E mutation.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate population: Tissue expression study in thyroid disease patients with no administration of thymosin beta-4, so it cannot inform treatment claims.
    • abstract only: Only the abstract is available in the record. Methods and sample details beyond the subset of differentiated thyroid cancer patients are not given.
    • inappropriate endpoint: Tissue expression of an endogenous protein is a surrogate and says nothing about the effect of giving thymosin beta-4.
    • confounding: A cross-sectional correlation cannot show causation, and the abstract gives no adjustment for confounders.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 36321670, abstract (sentences 7-8) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 36321670, abstract (sentences 2-3) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 36321670, abstract (sentence 5) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).